Novartis has begun construction on its new 46,000ft² RLT manufacturing facility in Denton, Texas, marking the latest step in its $23bn investment in US manufacturing and research.

Gilead’s HIV portfolio was a strong growth area for the company in Q1 2026. Credit: Tada Images / Shutterstock.com. Gilead Sciences has secured a good start to 2026 with its human immunodeficiency ...

Japan’s latest NHI drug price revision for FY26 has now come into effect, with an average 4.02% drop in prices on a spending basis across 15,800 products.

Angelini Pharma has signed a definitive agreement to acquire Catalyst Pharmaceuticals for a total equity value of nearly $4.1bn.

Autonomous labs guided by AI can operate with increasing independence and are beginning to outperform human researchers.

This deal aligns with GSK's focus on addressing the complications of obesity, while restocking its pipeline amid key patent expiries.

Ginkgo Bioworks CEO Jason Kelly discusses the company’s work on autonomous labs and their impact on biopharma R&D.

Halozyme Hypercon has signed an exclusive global collaboration and licence agreement with Oruka Therapeutics to develop ORKA-001 using Hypercon Technology.

Daiichi Sankyo has entered into a collaboration with Paris-based Waiv intended at digital pathology biomarker discovery for an ADC programme.

When Eli Lilly's Lebanon campus is complete, it will manufacture several of the pharma's APIs and genetic medicines to serve US patients.

As with its previous siRNA deal, Madrigal plans to explore whether gene-silencing could complement its lead drug Rezdiffra.

MSD has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML).